BergenBio Fundamentale Forhold (BGBIO)

[anon99889496]

Det var fornybar som begynnte

[fuzzy]

Accord studien skal uansett pushes til gjennomføring. Det er stort behov for å ha terapi tilgjengelig selv om vaksinene skulle vise seg å fungere mer eller mindre forventet og rulles ut i tide. Det må være alternativer tilgjengelig for de som ikke får ønsket virkning av vaksinen og backstop på delen av populasjonen som enten velger å ikke bli vaksinert, eller ikke får mulighet til det.

Om Bemcentinib vinner frem som beste kandidat er det en fantastisk anerkjennelse og vil få øynene opp hos så godt som alle mann alle, om de jobber innen finans eller medisin eller bare er investorer…

[Londonmannen]

Vi kan gjerne ønske å kjøre en studie kun på Bemcentinib, men da tror jeg man ville fåt enda færre pasienter til å gå frivillig inn i studien.

Her må vi bare akseptere opplegget. Og dette er ikke spesielt for Bemcentinib, men noe som vil gjelde alle medisinene som blit uttestet.

[Savepig]

Nei du har rett, men får desverre ikke flyttet pga den sedvanlige tekniske feilen

[Hayen]

Vi kan ta opp denne diskusjonen om et par måneder. Jeg er veldig sikker på at du tar helt feil.

[eiken]

Remdesivir er ute av behandling for lenge siden😀

[Mykle]

Et annet poeng er at Bemc kan gis et steg tidligere en de to andre nevnte preparatene. Dette ut i fra den 9 punkts skalaen fra WHO.

Får håpe de får fatt i mye pasienter på laveste punkt på skalaen, og dermed vil det være monoterapi.

Uansett flott de er i gang. Fremdeles 1500ish innleggelser daglig etter 1 måneds lockdown. De lettet på tiltakene 3. desember.

[eiken]

Og lengste effekt på immunitet etter vaksine er litt over 3 mnd.

[HBS]

Har du noen kilde på det??

[eiken]

Produsentene sier dette selv. Har ikke fremsatt lengde på immunitet av andre vaksine og hvor mange som tåles å gi.

[Hfyh]

Har lest dette jeg og, at 3 dose må gis 3 måneder etter dose 2, men tror det bare var 1 av produsentene.

[TekBot]

BerGenBio ASA: Extraordinary General Meeting today

Bergen, Norway, 9 December 2020 - Extraordinary General Meeting in BerGenBio ASA
is being held virtually today 9 December 2020 at 16:00 hours (CET).

…

Vis børsmeldingen

Information on how to join the meeting:

Webcast link: https://web.lumiagm.com/?fromUrl=127403163

Meeting ID: 127-403-163

Please note you must be logged in online before the meeting starts to be able to
vote on issues on the agenda. You will then be required to enter your ID: a)
reference number from VPS and b) PIN code from VPS

Guide for online participation can be found at www.bergenbio.com under Investors
/ General meetings

-Ends-

For further information, please contact:

Richard Godfrey CEO, BerGenBio ASA
+47 917 86 304

Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com
+47 917 86 513

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

[Biotec]

Hva gjelder denne?

[Saltimaten]

Utskiftinger i styret, om jeg husker rett.

[TekBot]

BERGENBIO ASA: EXTRAORDINARY GENERAL MEETING

Bergen, Norway, 9 December 2020 - Extraordinary General Meeting in
BerGenBio ASA was held virtually on 9 December 2020 at 16:00 hours (CET).

…

Vis børsmeldingen

All proposals were resolved as presented in the notice convening the
extraordinary general meeting distributed on 18 November 2020, as further set
out in the minutes from the extraordinary general meeting attached hereto
and available at https://www.bergenbio.com/investors/general-
meetings/ (https://www.bergenbio.com/investors/general-%20meetings/)

-Ends-

For further information, please contact:

Richard Godfrey CEO, BerGenBio ASA
+47 917 86?304

Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com
+47 917 86?513

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

[TekBot]

BERGENBIO TO PRESENT AN UPDATE ON THE ONGOING PHASE II STUDY OF BEMCENTINIB IN COMBINATION WITH PEMBROLIZUMAB IN REFRACTORY NSCLC AT WCLC 2020

Bergen, Norway, 16 December 2020 - BerGenBio ASA (OSE:BGBIO), a clinical-stage
biopharmaceutical company developing novel, selective AXL kinase inhibitors for
severe unmet medical need, is pleased to announce it has been accepted for an
…

Vis børsmeldingen

oral presentation at the 2020 World Conference on Lung Cancer Singapore (WCLC),
being held from 28-31 January 2021.

The oral presentation will provide an update from the Company’s Phase II study
of bemcentinib in combination with anti-PD-1 therapy pembrolizumab (BGBC008) in
refractory non-small cell lung cancer (NSCLC).

Abstract titles have been announced online, and details of the presentation are
below.

Title: A phase II study of the oral selective AXL inhibitor bemcentinib with
pembrolizumab in patients with advanced NSCLC

Presenting Author: Dr. Matthew G. Krebs PhD.

Session/Abstract ID: Immunotherapy (Phase II/III Trials) / # 3647

Date/Time: Friday 29[th] January 2021 at 09.50 Singapore Time / 02.50 CET

Further details can be found on the WCLC
website (https://library.iaslc.org/conference
-program?product_id=20&author=&category=&date=&session_type=&session=&presentatio
n=&keyword=bemcentinib&cme=undefined&)

The presentation will be available on BerGenBio’s website from 29 January 2021.

• END -

About AXL

AXL kinase is a cell membrane receptor and an essential mediator of the
biological mechanisms underlying life-threatening diseases. In cancer, AXL
suppresses the body’s immune response to tumours and drives cancer treatment
failure across many indications. AXL expression defines a very poor prognosis
subgroup in most cancers. AXL inhibitors, therefore, have potential high value
at the centre of cancer combination therapy, addressing significant unmet
medical needs and multiple high-value market opportunities. Research has also
shown that AXL mediates other aggressive diseases.

About Bemcentinib

Bemcentinib (formerly known as BGB324), is a potentially first-in-class
selective AXL inhibitor in a broad phase II clinical development programme.
Ongoing clinical trials are investigating bemcentinib in multiple solid and
haematological tumours, in combination with current and emerging therapies
(including immunotherapies, targeted therapies and chemotherapy), and as a
single agent. Bemcentinib targets and binds to the intracellular catalytic
kinase domain of AXL receptor tyrosine kinase and inhibits its activity.
Increase in AXL function has been linked to key mechanisms of drug resistance
and immune escape by tumour cells, leading to aggressive metastatic cancers.

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including immune-evasive, therapy resistant cancers. The
company’s proprietary lead candidate, bemcentinib, is a potentially first-in
-class selective AXL inhibitor in a broad phase II oncology clinical development
programme focused on combination and single agent therapy in lung cancer,
leukaemia and COVID-19. A first-in-class functional blocking anti-AXL antibody,
tilvestamab, is undergoing phase I clinical testing. In parallel, BerGenBio is
developing companion diagnostic tests to identify patient populations most
likely to benefit from bemcentinib: this is expected to facilitate more
efficient registration trials supporting a precision medicine-based
commercialisation strategy.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit www.bergenbio.com

Contacts

Richard Godfrey CEO, BerGenBio ASA
+47 917 86 304

Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com
+47 917 86 513

International Media Relations

Mary-Jane Elliott, Chris Welsh, Lucy Featherstone, Carina Jurs

Consilium Strategic Communications
bergenbio@consilium-comms.com
+44 20 3709 5700

Media Relations in Norway

Jan Petter Stiff, Crux Advisers

stiff@crux.no
+47 995 13 891

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

[Ekornet]

Er så latterlig bra!

[TekBot]

Flaggemelding - BGBIO

Investinor AS har den 16. desember 2020 inngått avtale med sitt heleide datterselskap, Investinor Direkte AS, om å overdra alle sine 7 270 780 aksjer i Bergenbio ASA, notert på Oslo Børs, til kurs NOK 36,0 per aksje. Ved gjennomføringen av transaksjonen vil Investinor Direkte AS eie 7 270 780 aksjer i Bergenbio ASA, tilsvarende ca. 8,3 % av aksjekapitalen og stemmerettighetene i Bergenbio ASA, og Investinor AS vil ikke eie aksjer eller rettigheter til aksjer i Bergenbio ASA.
…

Vis børsmeldingen

Kilde

[Flottesen]

Statens Direkte Økonomiske Engasjement, avdeling biotek?

[drdr]

Spekulasjon eller fakta?